Cited by 124Cannabis and Cannabinoid ResearchStress Responses and CortisolNeuroscience and Neuropharmacology Research

Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation

Open access
Sumislawski, Joshua J, Ramikie, Teniel S, Patel, Sachin·2011·Neuropsychopharmacology

Abstract

Chronic stress is the primary environmental risk factor for the development and exacerbation of affective disorders, thus understanding the neuroadaptations that occur in response to stress is a critical step in the development of novel therapeutics for depressive and anxiety disorders. Brain endocannabinoid (eCB) signaling is known to modulate emotional behavior and stress responses, and levels of the eCB 2-arachidonoylglycerol (2-AG) are elevated in response to chronic homotypic stress exposure. However, the role of 2-AG in the synaptic and behavioral adaptations to chronic stress is poorly understood. Here, we show that stress-induced development of anxiety-like behavior is paralleled by a transient appearance of low-frequency stimulation-induced, 2-AG-mediated long-term depression at GABAergic synapses in the basolateral amygdala, a key region involved in motivation, affective regulation, and emotional learning. This enhancement of 2-AG signaling is mediated, in part, via downregulation of the primary 2-AG-degrading enzyme monoacylglycerol lipase (MAGL). Acute in vivo inhibition of MAGL had little effect on anxiety-related behaviors. However, chronic stress-induced anxiety-like behavior and emergence of long-term depression of GABAergic transmission was prevented by chronic MAGL inhibition, likely via an occlusive mechanism. These data indicate that chronic stress reversibly gates eCB synaptic plasticity at inhibitory synapses in the amygdala, and in vivo augmentation of 2-AG levels prevents both behavioral and synaptic adaptations to chronic stress.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2011.166

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Systemically administered MAGL inhibitors acutely reduce anxiety-like behavior.

    “In this context, systemically administered MAGL inhibitors have been shown to acutely reduce anxiety-like behavior [75–78]”
  • Chronically administered MAGL inhibitors prevent chronic stress-induced increases in anxiety-like behavior and impairments in BLA synaptic plasticity.

    “and when administered chronically, to prevent chronic stress-induced increases in anxiety-like behavior and impairments in BLA synaptic plasticity [75]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 43 · Cited by 124

Authors
Sumislawski, J. J., Ramikie, T. S., & Patel, S.
Affiliations
Vanderbilt University (US)
Corresponding author
Patel, Sachin
Venue
Neuropsychopharmacology
Published
2011-08-17
Volume
36
Issue
13
Pages
2750-2761
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2008565294
Cited by
124
References
43
Citations by year
2026: 3 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 12 · 2021: 10 · 2020: 8 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 15 · 2013: 11 · 2012: 4
FWCI
7.26
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Vanderbilt University
  • School of Medicine, Vanderbilt University
  • National Institute of Mental Health (K08MH090412)
  • National Institute on Drug Abuse (R01DA011322)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
chronic stress, endocannabinoid system, 2-arachidonoylglycerol, monoacylglycerol lipase inhibition, basolateral amygdala, GABAergic synapses, long-term depression, synaptic plasticity, anxiety-like behavior, mood disorders
MeSH terms
Adaptation, Psychological, Amygdala, Animals, Anxiety Disorders, Arachidonic Acids, Chronic Disease, Disease Models, Animal, Glycerides, Male, Mice, Inbred ICR, Monoacylglycerol Lipases, Organ Culture Techniques, Piperidines, Stress, Psychological, Mice, Benzodioxoles, Cannabinoid Receptor Modulators, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review